• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25514 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2028     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endometriosis: which non-drug treatment measures are effective in adolescents and young adults]
2028     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions for young people not in employment, education or training (NEET)]
2028     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effect of IVF treatment at different BMI thresholds]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S2e guideline antibody screening for asymptomatic type 1 diabetes without hyperglycemia]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S2e guideline antibody screening for asymptomatic type 1 diabetes without hyperglycemia]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the Disease Management Program (DMP) for heart failure]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Preparation of a decision aid for interventions in nasal septum deviation or turbinate hypertrophy (second opinion)]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the regulations on early detection of skin cancer, taking into account possible risk-based screening and a possible adjustment of the frequency of examinations]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Urine strip test as part of the general health examination]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risk-adapted general health examination]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [One-time HIV test as part of the general health check-up]
2027     Norwegian Medical Products Agency (NOMA) [Endoscopic surgical interventions for disc herniation or spinal stenosis as supplement to current treatment]
2027     Canada’s Drug Agency (CDA-AMC) Anaplastic lymphoma kinase (ALK)-inhibitor sequencing for patients with ALK-positive non-small cell lung cancer
2027     Canada’s Drug Agency (CDA-AMC) Offloading devices for adults with diabetic foot ulcer
2027     Canada’s Drug Agency (CDA-AMC) Longevity of direct dental restorations
2027     Canada’s Drug Agency (CDA-AMC) At-home transcranial direct current stimulation (tDCS) devices for the treatment of depression
2027     Canada’s Drug Agency (CDA-AMC) Outpatient parenteral antibiotic therapy
2027     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Review of recommendations for the prevention of urinary tract infections in nursing homes and expert consensus]
2027     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic bronchoscopy integrated with cone-beam computed tomography for the diagnosis of pulmonary nodules]
2027     Scottish Health Technologies Group (SHTG) Specialist rehabilitation after major trauma
2027     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of portable blood analyzers in mobile emergency units]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of Alzheimer’s disease: What are the advantages and disadvantages of early diagnostic testing for asymptomatic individuals?]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for transarterial left heart catheterization]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migraine: do patients benefit from a low-sugar, low-fat or ketogenic diet?]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Additional carotid plaque imaging – Evidence report for the S3 guideline on the diagnosis, treatment and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risk-adapted screening for carotid plaques – Evidence report for the S3 guideline on the diagnosis, treatment and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carotid endarterectomy versus carotid stenting for asymptomatic stenosis – Evidence report for the S3 guideline on the diagnosis, treatment and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carotid stenting versus standard treatment for asymptomatic stenosis – Evidence report for the S3 guideline on the diagnosis, treatment and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on the diagnosis, therapy and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on the diagnosis, therapy and follow-up of extracranial carotid stenosis]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Equinus foot: which non-drug treatment methods are helpful for those affected?]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selection of interventions for the second opinion procedure according to §27b Social Code Book V]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in corrective surgery for esophageal atresia]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP ‘Obesity – adults’]
2027     Gesundheit Osterreich GmbH (GOeG) [Educational interventions to promote the rational prescribing of antibiotics for children and adolescents]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostics of endometriosis]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Methods, ways of working, and efforts to prevent recidivism for perpetrators of domestic or honor-based violence]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Home based health care: enablers and barriers to quality of care and patient safety]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostic accuracy of different index tests in diagnosing suspected peanut allergy]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Organisational and social work environment and mental ill-health]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [The dental care system’s opportunities to prevent and identify medical diagnoses and health conditions]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [A map of systematic reviews that have examined how sexual risk exposure can be identified or how mental illness among sexually exposed individuals can be treated]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions aimed at increasing physical activity in people with intellectual disabilities or autism spectrum disorder]
2027     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Extended postnatal home visiting programs]
2027     Norwegian Medical Products Agency (NOMA) [PIK3CA, PIK3R1, and PTEN alteration testing in colorectal cancer surgery patients to evaluate adjuvant acetylsalicylic acid treatment]
2027     Health Information and Quality Authority (HIQA) Health Technology Assessment (HTA) of the transition to, and coordination of, adult healthcare services for individuals with severe neurological impairment
2027     Health Information and Quality Authority (HIQA) A health technology assessment (HTA) of cochlear implants for adults with (1) single-sided deafness or (2) bilateral severe-to-profound sensorineural hearing loss who previously received one implant.
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety and panic disorder: do those affected benefit from the "emotional freedom technique”?]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Short frenulum in infants: what are the advantages and disadvantages of frenectomy (cutting the frenulum) compared to, for example, breastfeeding counseling for breastfeeding problems?]
2027     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of endovascular treatment using transarterial radioembolization for intermediate and advanced hepatocellular carcinoma]
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026     Agency for Healthcare Research and Quality (AHRQ) Predictors, consequences, and organizational interventions for burnout among healthcare workers: a systematic review of longitudinal studies
2026     Agency for Healthcare Research and Quality (AHRQ) Primary hypofractionated radiation therapy for localized prostate cancer
2026     Agency for Healthcare Research and Quality (AHRQ) The performance of fusion and interventional pain procedures for degenerative diseases of the lumbar spine
2026     Agency for Healthcare Research and Quality (AHRQ) Mindfulness-based interventions for well-being and mental health in children and adolescents
2026     Agency for Healthcare Research and Quality (AHRQ) Medical care for adults with Down syndrome
2026     Agency for Healthcare Research and Quality (AHRQ) Prehospital EMS blood transfusion and fluid interventions for hemorrhagic shock
2026     Agency for Care Effectiveness (ACE) Biology-guided radiotherapy for treatment of lung or bone tumours in adults
2026     Agency for Care Effectiveness (ACE) DermaSensor as an adjunctive diagnostic tool for lesions suspicious for skin cancer
2026     Agency for Care Effectiveness (ACE) Symani surgical system for open microsurgery
2026     Agency for Care Effectiveness (ACE) Intracardiac monitor for acute coronary syndrome (ACS) event detection
2026     Agency for Care Effectiveness (ACE) Positive airway pressure for moderate-to-severe obstructive sleep apnoea
2026     Agency for Care Effectiveness (ACE) Biologics for treating atopic dermatitis
2026     Agency for Care Effectiveness (ACE) Icatibant and sebetralstat for treating hereditary angioedema attacks
2026     Agency for Care Effectiveness (ACE) Equecabtagene autoleucel for relapsed or refractory multiple myeloma
2026     Agency for Care Effectiveness (ACE) Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer
2026     Agency for Care Effectiveness (ACE) RSVpreF maternal vaccine for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants
2026     Agency for Care Effectiveness (ACE) Clesrovimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
2026     Agency for Care Effectiveness (ACE) Brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
2026     Agency for Care Effectiveness (ACE) Osimertinib for maintenance treatment of locally advanced, unresectable EGFR mutation-positive non-small-cell lung cancer during or following chemoradiation therapy
2026     Agency for Care Effectiveness (ACE) Nivolumab and relatlimab for first-line treatment of unresectable or metastatic melanoma
2026     Agency for Care Effectiveness (ACE) Durvalumab for treating resectable gastric or gastroesophageal junction adenocarcinoma
2026     Agency for Care Effectiveness (ACE) Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours
2026     Agency for Care Effectiveness (ACE) Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps
2026     Agency for Care Effectiveness (ACE) Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation
2026     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant
2026     Agency for Care Effectiveness (ACE) Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
2026     Agency for Care Effectiveness (ACE) Maribavir for treating refractory or drug-intolerant cytomegalovirus infection after transplant
2026     Agency for Care Effectiveness (ACE) Vutrisiran for transthyretin amyloid cardiomyopathy
2026     Andalusian Health Technology Assessment Area (AETSA) [Systems for the estimation of coronary flow and myocardial perfusion through angiographic analysis software]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Chronic obstructive pulmonary disease: performing diagnostic pre-/postbronchodilator spirometry and interpreting the results]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Multiple sclerosis in the era of the new McDonald criteria]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Living environments for seniors experiencing a loss of independence]
2026     Health Sciences Institute in Aragon (IACS) [Criteria for designing primary care training programs on mental health and suicide prevention in children and adolescents]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Latent infection screening before initiating immunosuppressive cancer treatment]
2026     National Institute for Health and Care Excellence (NICE) Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment. NICE HealthTech guidance 781
2026     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 1191
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1190
2026     National Institute for Health and Care Excellence (NICE) Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years. NICE technology appraisal guidance 1192
2026     National Institute for Health and Care Excellence (NICE) Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable. NICE technology appraisal guidance 1193
2026     National Institute for Health and Care Excellence (NICE) Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 1194
2026     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 1195
2026     HTA Region Stockholm [Consequences of replacing chest x-ray with ultra-low-dose computed tomography in patients with a low suspicion of lung cancer]
2026     HTA South [Camera-based autofluorescence during total thyroidectomy]
2026     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) AIRe – multidisciplinary rehabilitation platform
2026     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) BitHabit® – application for lifestyle guidance and mental wellbeing
2026     Basque Office for Health Technology Assessment (OSTEBA) [Telemonitoring and computerised management of patients receiving home dialysis and rehabilitation]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Detection of dihydropyrimidine dehydrogenase deficiency prior to fluoropyrimidine-based chemotherapy]
2026     Canada’s Drug Agency (CDA-AMC) Teleoptometry for eye exams